Epidemiology of obstruction, exacerbations and hyperreactivity. Effects of glucocorticosteroids and other anti-inflammatory treatment.
Validated and standardized questions are available for self-reporting of exacerbations of symptoms due to bronchopulmonary infections but not for non-infective exacerbations. The presence of non-specific bronchial hyperresponsiveness may help to identify smokers with a high risk of rapid decline in lung function, but change in bronchial responsiveness with treatment probably cannot be used to predict subsequent long-term progression in FEV1. In non-asthmatic individuals three months' treatment with glucocorticosteroids has not improved FEV1 nor reduced bronchial responsiveness; the effects of glucocorticosteroids on bronchial secretions and infections and long-term decline in FEV1 are largely unknown.